Marktinformationen

WASHINGTON (dpa-AFX) - Novo Nordisk announced that the CLARION-CKD phase 3
trial failed to meet its primary endpoint. The company added that it will
recognise an impairment loss of around DKK 5.7 billion related to the intangible
asset ocedurenone in the second quarter of 2024.

Novo Nordisk acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023. The
phase 3 lead indication trial CLARION-CKD, which investigated ocedurenone in
patients with uncontrolled hypertension and advanced chronic kidney disease, was
conducted by KBP Biosciences.

The trial design included a prespecified interim analysis after all trial
participants had completed 12 weeks of treatment. Based on the interim analysis,
an independent data monitoring committee concluded that the trial met the
prespecified futility criteria - meaning that the trial did not meet its primary
endpoint of change in systolic blood pressure from baseline to week 12. As a
result, Novo Nordisk has decided to stop the CLARION-CKD trial.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX